We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and future types of  cancers. We are committed to building on our established Conjugation technology platform in addition to introducing new innovations to the novel mRNA technology to utilize it in the most reliable way. Allowing us to be at the forefront of patient response when it comes to cancer treatements, affecting millions of people every year. 

HPV (high valency) Vaccine – IVIV 820

• Platform – Conjugation
• Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family, Many HPV infections cause no symptoms, and 90% resolve within two years, however in some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis, anus, mouth, tonsils, or throat. Nearly all cervical cancer are due to HPV; two strains, HPV16 and HPV18, account for 70% of cases. HPV16 is responsible for almost 90% of HPV positive, oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV. HPV is the most common sexually transmitted infection (STI) globally. Worldwide an estimated 569,000 new cases of cervical cancer occur annually , with 311,000 deaths. Around 85% of these cervical cancers occurred in low and middle-income countries. In the United States, about 30,700 cases of cancer due to HPV occur each year.

We at InventVacc, believe the world needs a mix of traditional and innovative approaches in the prevention of both known and yet to be discovered rare diseases. There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people worldwide are currently suffering from rare diseases without reliable treatment or prophylaxis.  We are committed to building on our established Conjugation technology platform in addition to introducing new innovations to the novel mRNA technology to utilize it in the most reliable way allowing us to be at the forefront of patient response when it comes to rare diseases threats, affecting millions of people every year. 

Haemophilus Influenza Type A Vaccine (Hia) - IVIV  378

• Platform: Conjugation Technology
• Hemophilus Influenza A was recognized as an important pathogen causing severe infections in young children. Remarkably, the highest incidence rates of invasive Hia disease are found in North American Indigenous populations, specifically Indigenous tribes of Navajo and Inuit. In these populations Hia has become the leading cause of bacterial meningitis among children.